Because the downregulation of Myo10 is responsible for the therapeutic action of KDIP on colorectal tumours with higher KITENIN expression, we propose that KDIP could be used as a dual blocker to the oncogenic function of both KITENIN and Myo10 proteins. The gene discussed is VANGL1; the disease is colorectal neoplasm.